Ranbaxy's Court Win On Lipitor Generics Leaves Compliance Issues Unanswered
This article was originally published in PharmAsia News
Executive SummaryIndia's Ranbaxy Laboratories may have been freed to launch a U.S. generic of the world's best-selling drug if it gets U.S. FDA approval, but a court's action allowing it to do so failed to settle several issues roiling within the pharmaceutical industry
You may also be interested in...
Plaintiff Peter Lurie, former US FDA associate commissioner, expects results of hundreds of clinical trials of approved drugs will become available under ruling against HHS; co-plaintiff sought eteplirsen study data.